Drug Profile
VXA CoV2 1
Alternative Names: Corona virus vaccine - VAXART; COVID-19 (SARS-CoV-2) E1-/E3-deleted replication defective recombinant adenovirus 5 with dsRNA adjuvant oral tablet vaccine; Non replicating Ad5 adjuvanted oral tableted vaccine; Oral SARS-CoV2 vaccine; Oral Tableted Ad5 COVID-19 Vaccine; SARS-CoV2 vaccine - VAXART; VXA-CoV2-1Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Vaxart
- Class COVID-19 vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in USA (PO, Tablet)
- 20 Jul 2022 Updated immunogenicity data from a phase I trial in COVID-2019 infections released by Vaxart
- 24 Feb 2022 Pharmacodynamic data from a preclinical trial in COVID-2019 infections released by Vaxart